My investment strategy is simple. Find small-cap undervalued biotech companies with promising drugs and significant short and long term upside.
Maxim Group analyst Jason Kolbert is out today with his second note this week on OncoSec Medical (OTC:ONCS) maintaining a Buy rating with a $3.00 …
In a research report sent to investors today, Maxim Group analyst Jason Kolbert reiterated a Buy rating on OncoSec Medical (OTC:ONCS) with a …
Maxim Group analyst Jason Kolbert maintained a Buy rating on OncoSec Medical (OTC:ONCS) with a price target of $3.00, as the company announced a …
In a research report sent to investors today, H.C.
